Home › Compare › AICOF vs MRK

AICOF vs MRK: Dividend Comparison 2026

AICOF yields 200000.00% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AICOF wins by $4.911780474428384e+29M in total portfolio value
10 years
AICOF
AICOF
● Live price
200000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.911780474428384e+29M
Annual income
$490,695,411,370,591,700,000,000,000,000,000,000.00
Full AICOF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — AICOF vs MRK

📍 AICOF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAICOFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AICOF + MRK cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
AICOF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AICOF
Annual income on $10K today (after 15% tax)
$17,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$417,091,099,665,002,940,000,000,000,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, AICOF beats the other by $417,091,099,665,002,940,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AICOF + MRK for your $10,000?

AICOF: 50%MRK: 50%
100% MRK50/50100% AICOF
Portfolio after 10yr
$2.455890237214192e+29M
Annual income
$245,347,705,685,295,860,000,000,000,000,000,000.00/yr
Blended yield
99.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

AICOF
No analyst data
Altman Z
-22.1
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AICOF buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAICOFMRK
Forward yield200000.00% ✓2.76%
Annual dividend / share$2.00$3.32 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7% ✓
Portfolio after 10y$4.911780474428384e+29M$56.8K ✓
Annual income after 10y$490,695,411,370,591,700,000,000,000,000,000,000.00 ✓$9,798.13
Total dividends collected$4.911464459982279e+29M$28.9K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AICOF vs MRK ($10,000, DRIP)

YearAICOF PortfolioAICOF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$20,010,700$20,000,000.00$11,206$366.19+$20.00M → AICOF
2$37,424,589,019$37,403,177,570.09$12,650$502.35+$37424.58M → AICOF
3$65,416,215,188,220$65,376,170,877,969.18$14,407$694.19+$65416215.17M → AICOF
4$106,868,230,495,008,900$106,798,235,144,757,520.00$16,585$967.82+$106868230494.99M → AICOF
5$163,172,871,735,896,870,000$163,058,522,729,267,200,000.00$19,342$1,363.89+$163172871735896.84M → AICOF
6$232,854,599,801,468,860,000,000$232,680,004,828,711,460,000,000.00$22,913$1,947.19+$232854599801468864.00M → AICOF
7$310,570,858,137,017,100,000,000,000$310,321,703,715,229,540,000,000,000.00$27,662$2,823.89+$310570858137017057280.00M → AICOF
8$387,148,154,301,613,200,000,000,000,000$386,815,843,483,406,600,000,000,000,000.00$34,159$4,173.35+$3.871481543016132e+23M → AICOF
9$451,061,749,763,281,040,000,000,000,000,000$450,647,501,238,178,360,000,000,000,000,000.00$43,337$6,308.80+$4.510617497632811e+26M → AICOF
10$491,178,047,442,838,440,000,000,000,000,000,000$490,695,411,370,591,700,000,000,000,000,000,000.00$56,776$9,798.13+$4.911780474428384e+29M → AICOF

AICOF vs MRK: Complete Analysis 2026

AICOF — Stock

Generative AI Solutions Corp., an artificial intelligence company, focuses on development and commercialization of AI-powered tools and solutions for businesses and consumers across various industries in Canada. The company offers MAI Cloud, a cloud-based database; Remitz, which identifies and submits claims related to medical billing; and Classmate app, which utilizes natural language processing to find answers to educational questions. It also provides AI-powered products and services, including predictive analytics tools, chatbots, and machine learning platforms. In addition, the company is developing Tobacco Titan for the tobacco industry; and Global AI Newswire, which sends real-time press releases of publicly listed companies to users. It serves customers in education, healthcare, finance, and transportation industries. Generative AI Solutions Corp. is headquartered in Vancouver, Canada.

Full AICOF Calculator →

MRK — Healthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this AICOF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AICOF vs SCHDAICOF vs JEPIAICOF vs OAICOF vs KOAICOF vs MAINAICOF vs JNJAICOF vs ABBVAICOF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.